Caribou Biosciences, Inc. (CRBU) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Caribou Biosciences is a clinical-stage biopharmaceutical company developing allogeneic (off-the-shelf) CAR-T cell therapies using its CRISPR genome-editing platform. The company has no approved products and generates revenue primarily through licensing and collaboration agreements. As of the reporting date, the company is classified as an emerging growth company and a smaller reporting company.
Key Financial Metrics
| Metric (in thousands) | Q2 2024 | Q2 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Licensing & Collaboration Revenue | $3,464 | $3,755 | $5,893 | $7,257 |
| Net Loss | $(37,697) | $(29,519) | $(78,931) | $(57,563) |
| Loss Per Share (Basic/Diluted) | $(0.42) | $(0.48) | $(0.88) | $(0.94) |
| Cash, Cash Equivalents & Marketable Securities | $311.8 million (as of June 30, 2024) | |||
| Accumulated Deficit | $378.2 million (as of June 30, 2024) | |||
| Net Cash Used in Operating Activities (YTD) | $(70.1 million) | $(43.1 million) |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased by 7.7% in Q2 and 18.8% YTD compared to the prior year. This was primarily driven by the termination of the AbbVie collaboration agreement (which contributed $1.4M in Q2 2023 and $3.0M YTD 2023). This decline was partially offset by new revenue from Pfizer ($0.6M in Q2) and Edge Animal Health ($1.6M in Q2).
- Increased Operating Expenses: Total operating expenses rose to $47.0M in Q2 (up $10.3M YoY) and $95.4M YTD (up $24.2M YoY).
- R&D Expenses: Increased to $35.5M in Q2 due to higher external CRO/CMO costs for clinical trials, increased personnel costs, and other R&D activities.
- G&A Expenses: Increased to $11.5M in Q2, driven by higher personnel costs and legal fees, including a $3.9M accrual for a securities litigation settlement.
- Other Income: Total other income increased significantly due to a $1.8M gain from the change in fair value of the MSKCC success payments liability and higher interest income from marketable securities.
Outlook, Risks, and Unusual Items
- Liquidity: Management expects existing cash and marketable securities ($311.8M) to fund operations for at least the next 12 months. The company continues to rely on equity financing, debt, or collaborations to sustain operations.
- Subsequent Event (Workforce Reduction): On July 16, 2024, the company announced the discontinuation of its allogeneic CAR-NK platform and a workforce reduction of 21 positions (~12%). This is expected to incur $0.5M–$1.0M in costs in Q3 2024 but will extend the cash runway into the second half of 2026.
- Litigation: The company reached an agreement in principle to settle the Bergman securities class action lawsuit for $3.9M. The settlement agreement was filed with the court in June 2024 pending approval. A parallel state court case (Lowry) was dismissed.
- Clinical Pipeline: The company is advancing CB-010 (anti-CD19 CAR-T) in the ANTLER trial, with plans to initiate a pivotal Phase 3 trial in late 2025 pending FDA agreement. CB-011 (anti-BCMA) and CB-012 (anti-CLL-1) are in Phase 1 dose escalation.
Investor Verification Checklist
- Cash Runway: Verify the impact of the July 2024 workforce reduction on the projected 12-month liquidity runway.
- Litigation Settlement: Monitor court approval status of the $3.9M Bergman settlement and any potential additional legal costs.
- Revenue Concentration: Review the sustainability of revenue streams from related parties (Pfizer, Edge Animal Health) following the loss of AbbVie revenue.
- Clinical Milestones: Track enrollment and data readouts for the ANTLER (CB-010) and CaMMouflage (CB-011) trials, specifically the impact of partial HLA matching on efficacy.
- Capital Needs: Assess the timeline for potential future capital raises given the extended burn rate and the decision to discontinue the CAR-NK platform.